Kintaro Cells Power Corporation, a leading authority on stem cell technology and stem cell treatment, will be visiting Bahrain between 1st October and the 8th October 2019. Kintaro representatives will attend the Majlis of H.R.H Crown Prince, Deputy Supreme Commander and First Deputy Prime Minister of the Kingdom of Bahrain on 2nd October 2019.
Stem cell technology and treatments are pushing the boundaries of human development, body repair, organ function replenishment and well-being. These new procedures are currently at the forefront of pioneering new medical research and development.
The company develops and manufactures “KINTARO Cells®” a stem cell technology which has the potential to treat and prevent diseases, medical anti-aging, recovery after surgery and much more.
Not very long ago, regenerative medicine was perceived as a subject matter of the future; something that could only be dreamt of. Currently, there are certain medical treatments that are being popularised including skin transplantation. Regenerative medicine techniques also include rehabilitation and restoration of functions to artificial arms, artificial legs and artificial joints. However, the future of regenerative medicine is aimed at regenerating damaged internal organs and tissues by the utilisation of stem cell treatments.
Appointments will be available on request, subject to availability, at the Crowne Plaza Hotel between 2nd October to 8th October. Contact email@example.com
Dr. Denys Bilko is the Director of Biotechnology of Kintaro Cells Power. He has pursued both academic and technological aspects of theoretical and practical biology and biotechnology, undertaking many certification programs related to project management, good manufacturing practices, quality management and regulatory requirements.
His extensive practical experience at national and international levels allows for a broad and comprehensive understanding of the subject development, production and testing of the cell and tissue biotechnology and product development according to the complexities of GMP, GLP and GDP practices.